Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF IMMUNOLOGY
Volume 46, Issue 1, Pages 230-241
Publisher
Wiley
Online
2015-10-31
DOI
10.1002/eji.201545708
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IL-22, cell regeneration and autoimmunity
- (2015) Enayat Nikoopour et al. CYTOKINE
- FactoMineR: AnRPackage for Multivariate Analysis
- (2015) Sébastien Lê et al. Journal of Statistical Software
- Reduction in CD4 Central Memory T-Cell Subset in Costimulation Modulator Abatacept-Treated Patients With Recent-Onset Type 1 Diabetes Is Associated With Slower C-Peptide Decline
- (2014) T. Orban et al. DIABETES
- Delayed Anti-CD3 Therapy Results in Depletion of Alloreactive T Cells and the Dominance of Foxp3+CD4+Graft Infiltrating Cells
- (2013) R. Goto et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders
- (2013) K. C. Herold et al. DIABETES
- Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes: Two-Year Results From the Randomized, Placebo-Controlled Protege Trial
- (2013) W. Hagopian et al. DIABETES
- Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial
- (2013) Mark R Rigby et al. Lancet Diabetes & Endocrinology
- Induction of Allograft Tolerance by Monoclonal CD3 Antibodies: A Matter of Timing
- (2012) S. You et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
- (2012) K. C. Herold et al. DIABETOLOGIA
- Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients
- (2012) Ken T. Coppieters et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Teplizumab Induces Human Gut-Tropic Regulatory Cells in Humanized Mice and Patients
- (2012) F. Waldron-Lynch et al. Science Translational Medicine
- Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6
- (2011) Wenda Gao et al. CELL CYCLE
- An Allele ofIKZF1(Ikaros) Conferring Susceptibility to Childhood Acute Lymphoblastic Leukemia Protects Against Type 1 Diabetes
- (2011) Austin D.-E. Swafford et al. DIABETES
- Peripheral and Islet Interleukin-17 Pathway Activation Characterizes Human Autoimmune Diabetes and Promotes Cytokine-Mediated -Cell Death
- (2011) S. Arif et al. DIABETES
- NKG2A is a marker for acquisition of regulatory function by human CD8+T cells activated with anti-CD3 antibody
- (2011) Vitaly Ablamunits et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial
- (2011) Nicole Sherry et al. LANCET
- Control of TH17 cells occurs in the small intestine
- (2011) Enric Esplugues et al. NATURE
- Acquisition of regulatory function by human CD8+ T cells treated with anti-CD3 antibody requires TNF
- (2010) Vitaly Ablamunits et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients
- (2009) B. Keymeulen et al. BLOOD
- Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years
- (2009) Kevan C. Herold et al. CLINICAL IMMUNOLOGY
- Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies
- (2009) Simona Cernea et al. CLINICAL IMMUNOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started